Article

A 75-year-old man with an asymptomatic pleural-based mass discovered on routine chest radiographs. Primary pleural thymoma.

Department of Pathology, University of Manitoba, Winnipeg, Canada.
Archives of pathology & laboratory medicine (Impact Factor: 2.88). 05/2006; 130(4):e62-5. DOI: 10.1043/1543-2165(2006)130[e62:AYMWAA]2.0.CO;2
Source: PubMed
0 Followers
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This case study describes a 34-year-old woman presenting with a subacute history of dyspnoea associated with pleural based masses and pulmonary infiltrates. A computed tomography guided biopsy confirmed the presence of a pleural based thymoma, and a video assisted thoracoscopic lung biopsy revealed the pulmonary infiltrates to be a lymphocytic interstitial pneumonitis (LIP). The thymomas responded successfully to chemotherapy and the LIP improved following corticosteroid therapy.
    Case Reports 05/2009; 2009. DOI:10.1136/bcr.09.2008.0999
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet derived growth factor receptor beta (PDGFRbeta). PDGFRbeta is often overexpressed in mesothelioma cells and is a therapeutic target for imatinib in some solid tumours. A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma. Cultures from mesothelioma MMP, REN and ISTMES2 cell lines were treated with imatinib alone or in combination with a chemotherapeutic agent. Imatinib induced cytotoxicity and apoptosis selectively on PDGFRbeta positive mesothelioma cells via blockade of receptor phosphorylation and interference with the Akt pathway. Of the chemotherapeutic agents tested in combination with imatinib, a synergistic effect was obtained with gemcitabine and pemetrexed. This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.
    Thorax 09/2007; 62(8):690-5. DOI:10.1136/thx.2006.069872 · 8.56 Impact Factor